One-year longitudinal association between changes in dietary choline or betaine intake and cardiometabolic variables in the PREvención con DIeta MEDiterránea-Plus (PREDIMED-Plus) trial.
Mediterranean diet
betaine
cardiometabolic parameters
cardiovascular disease risk
choline
renal variables
Journal
The American journal of clinical nutrition
ISSN: 1938-3207
Titre abrégé: Am J Clin Nutr
Pays: United States
ID NLM: 0376027
Informations de publication
Date de publication:
19 12 2022
19 12 2022
Historique:
received:
10
11
2021
accepted:
09
09
2022
pubmed:
21
9
2022
medline:
21
12
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
Choline and betaine intakes have been related to cardiovascular health. We aimed to explore the relation between 1-y changes in dietary intake of choline or betaine and 1-y changes in cardiometabolic and renal function traits within the frame of the PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial. We used baseline and 1-y follow-up data from 5613 participants (48.2% female and 51.8% male; mean ± SD age: 65.01 ± 4.91 y) to assess cardiometabolic traits, and 3367 participants to assess renal function, of the Spanish PREDIMED-Plus trial. Participants met ≥3 criteria of metabolic syndrome and had overweight or obesity [BMI (in kg/m2) ≥27 and ≤40]. These criteria were similar to those of the PREDIMED parent study. Dietary intakes of choline and betaine were estimated from the FFQ. The greatest 1-y increase in dietary choline or betaine intake (quartile 4) was associated with improved serum glucose concentrations (-3.39 and -2.72 mg/dL for choline and betaine, respectively) and HbA1c levels (-0.10% for quartile 4 of either choline or betaine intake increase). Other significant changes associated with the greatest increase in choline or betaine intake were reduced body weight (-2.93 and -2.78 kg, respectively), BMI (-1.05 and -0.99, respectively), waist circumference (-3.37 and -3.26 cm, respectively), total cholesterol (-4.74 and -4.52 mg/dL, respectively), and LDL cholesterol (-4.30 and -4.16 mg/dL, respectively). Urine creatinine was reduced in quartile 4 of 1-y increase in choline or betaine intake (-5.42 and -5.74 mg/dL, respectively). Increases in dietary choline or betaine intakes were longitudinally related to improvements in cardiometabolic parameters. Markers of renal function were also slightly improved, and they require further investigation.This trial was registered at https://www.isrctn.com/ as ISRCTN89898870.
Sections du résumé
BACKGROUND
Choline and betaine intakes have been related to cardiovascular health.
OBJECTIVES
We aimed to explore the relation between 1-y changes in dietary intake of choline or betaine and 1-y changes in cardiometabolic and renal function traits within the frame of the PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial.
METHODS
We used baseline and 1-y follow-up data from 5613 participants (48.2% female and 51.8% male; mean ± SD age: 65.01 ± 4.91 y) to assess cardiometabolic traits, and 3367 participants to assess renal function, of the Spanish PREDIMED-Plus trial. Participants met ≥3 criteria of metabolic syndrome and had overweight or obesity [BMI (in kg/m2) ≥27 and ≤40]. These criteria were similar to those of the PREDIMED parent study. Dietary intakes of choline and betaine were estimated from the FFQ.
RESULTS
The greatest 1-y increase in dietary choline or betaine intake (quartile 4) was associated with improved serum glucose concentrations (-3.39 and -2.72 mg/dL for choline and betaine, respectively) and HbA1c levels (-0.10% for quartile 4 of either choline or betaine intake increase). Other significant changes associated with the greatest increase in choline or betaine intake were reduced body weight (-2.93 and -2.78 kg, respectively), BMI (-1.05 and -0.99, respectively), waist circumference (-3.37 and -3.26 cm, respectively), total cholesterol (-4.74 and -4.52 mg/dL, respectively), and LDL cholesterol (-4.30 and -4.16 mg/dL, respectively). Urine creatinine was reduced in quartile 4 of 1-y increase in choline or betaine intake (-5.42 and -5.74 mg/dL, respectively).
CONCLUSIONS
Increases in dietary choline or betaine intakes were longitudinally related to improvements in cardiometabolic parameters. Markers of renal function were also slightly improved, and they require further investigation.This trial was registered at https://www.isrctn.com/ as ISRCTN89898870.
Identifiants
pubmed: 36124652
pii: S0002-9165(23)03691-2
doi: 10.1093/ajcn/nqac255
pmc: PMC9761742
doi:
Substances chimiques
Betaine
3SCV180C9W
Choline
N91BDP6H0X
Banques de données
ISRCTN
['ISRCTN89898870']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1565-1579Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/S020845/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition.
Références
Br J Nutr. 2010 Jun;103(12):1808-16
pubmed: 20102675
Am J Physiol Gastrointest Liver Physiol. 2010 Nov;299(5):G1068-77
pubmed: 20724529
Diabetes Care. 2015 Feb;38(2):e13-4
pubmed: 25614692
Biosci Rep. 2020 Aug 28;40(8):
pubmed: 32756866
Nutr Today. 2018 Nov-Dec;53(6):240-253
pubmed: 30853718
Nutrition. 2019 Jun;62:7-17
pubmed: 30822745
Nutrition. 2017 Jan;33:28-34
pubmed: 27908547
Nutrients. 2018 Dec 07;10(12):
pubmed: 30544535
Am J Clin Nutr. 2021 Oct 4;114(4):1342-1350
pubmed: 34091663
Clin Nutr. 2021 Aug;40(8):4971-4979
pubmed: 34364236
Sports Med. 2021 Feb;51(2):243-253
pubmed: 33064295
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(9):746-754
pubmed: 29129852
Br J Nutr. 2015 Dec 28;114(12):2046-55
pubmed: 26423357
Int J Epidemiol. 2019 Apr 1;48(2):387-388o
pubmed: 30476123
Nat Med. 2013 May;19(5):576-85
pubmed: 23563705
Diabetes Care. 2014 Dec;37(12):3294-300
pubmed: 25404660
Appl Physiol Nutr Metab. 2020 Jul;45(7):737-744
pubmed: 31917604
Diabetes Care. 2020 Nov;43(11):2840-2846
pubmed: 32900787
Mol Nutr Food Res. 2019 Mar;63(5):e1800605
pubmed: 30548819
Br J Nutr. 2012 Oct;108(7):1264-71
pubmed: 22172554
J Proteome Res. 2015 Jan 2;14(1):531-40
pubmed: 25353684
Diabetes Care. 2019 May;42(5):777-788
pubmed: 30389673
Am J Clin Nutr. 2008 Feb;87(2):424-30
pubmed: 18258634
Am J Clin Nutr. 2017 Sep;106(3):888-894
pubmed: 28724646
Metabolism. 2013 Mar;62(3):400-10
pubmed: 23021013
Br J Nutr. 2021 Feb 28;125(4):440-447
pubmed: 32616104
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Nutr Metab (Lond). 2008 Feb 20;5:6
pubmed: 18289377
Nutrients. 2020 Oct 13;12(10):
pubmed: 33066009
Front Pharmacol. 2019 Nov 19;10:1360
pubmed: 31803054
Food Funct. 2018 Aug 15;9(8):4469-4479
pubmed: 30073224
Diabetes Metab Res Rev. 2013 Nov;29(8):607-17
pubmed: 23794489
J Am Coll Nutr. 2018 Nov-Dec;37(8):716-723
pubmed: 29764315
Nutr Rev. 2009 Nov;67(11):615-23
pubmed: 19906248
Am J Nephrol. 2021;52(1):45-58
pubmed: 33556935
Nutrients. 2020 Jul 27;12(8):
pubmed: 32726990
Free Radic Biol Med. 2011 Mar 1;50(5):567-75
pubmed: 21163346
N Engl J Med. 2013 Apr 4;368(14):1279-90
pubmed: 23432189
Eur J Nutr. 2020 Dec;59(8):3857-3861
pubmed: 32198672
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Coll Cardiol. 2016 Jun 7;67(22):2620-8
pubmed: 27256833
Am J Clin Nutr. 2018 Jul 1;108(1):163-173
pubmed: 29982310
J Am Heart Assoc. 2016 Jun 10;5(6):
pubmed: 27287696
Public Health Nutr. 2005 Oct;8(7):920-7
pubmed: 16277809
Sci Rep. 2019 Oct 30;9(1):15580
pubmed: 31666590
Nutrients. 2018 Oct 16;10(10):
pubmed: 30332744
Lipids. 2017 Mar;52(3):255-263
pubmed: 28091798
Nature. 2011 Apr 7;472(7341):57-63
pubmed: 21475195
Am J Clin Nutr. 2014 Sep;100(3):778-86
pubmed: 24944063
Nutrients. 2018 Feb 27;10(3):
pubmed: 29495543
J Card Fail. 2015 Feb;21(2):91-6
pubmed: 25459686
N Engl J Med. 2013 Apr 25;368(17):1575-84
pubmed: 23614584
Diabetologia. 2013 Dec;56(12):2549-51
pubmed: 24092493
PLoS One. 2017 Jan 13;12(1):e0168148
pubmed: 28085886
BMJ Open Sport Exerc Med. 2017 Mar 1;2(1):e000143
pubmed: 28879026
Am J Clin Nutr. 2006 Apr;83(4):905-11
pubmed: 16600945